key: cord-0934066-zzlofp4i
authors: Blais, Joseph E.; Wei, Yue; Chui, Celine S. L.; Chan, Esther W.; Wong, Ian C. K.
title: Inconsistent Safety Outcome Reporting in Randomized Clinical Trials of COVID-19 Vaccines Complicates Informed Medical Decisions
date: 2021-08-17
journal: Drug Saf
DOI: 10.1007/s40264-021-01108-5
sha: 1c1064233cc877668c6619a601227937bf4d69f1
doc_id: 934066
cord_uid: zzlofp4i

nan

. The International Conference on Harmonisation defines adverse events as "Any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment" [5] . In contrast, an adverse reaction is an event that is judged to be caused by the vaccine under study. In the published papers by Wu et al. and Zhang et al., there appears to be a lack of clarity in the reporting as both terms are used somewhat interchangeably. There are also discrepancies between the primary outcome of adverse reactions in the study protocols and adverse events in the statistical analysis plans.

To date, the Government of Hong Kong has purchased three COVID-19 vaccines that use three different vaccine platform technologies: Comirnaty (COVID-19 mRNA Vaccine [nucleoside-modified]; BioNTech Manufacturing GmbH, Mainz, Germany), CoronaVac, and Vaxzevria. To emphasize the importance of consistent, clear, and transparent reporting of safety outcomes in published articles of COVID-19 vaccine randomized clinical trials, a summary of the frequency of adverse events or reactions reported in clinical trials after the first dose of these three vaccines is shown in Table 1 . Published rates of adverse reactions for CoronaVac appear to be lower when compared with Comirnaty and Vaxzevria. It is not clear to us whether the investigators of CoronaVac used different definitions or different processes to ascertain whether an adverse event qualified as an adverse reaction, which could have resulted in a much lower frequency of reported adverse reactions when compared with Comirnaty and Vaxzevria, but this is difficult to ascertain from the published article. Tools created by the Brighton Collaboration [6] , which establishes consistent definitions for adverse events following immunization, have been endorsed and recommended by the World Health Organization's Global Advisory Committee on Vaccine Safety [7] . If vaccine developers used the safety templates and reported accordingly, it would greatly facilitate this area of discussion.

Moreover, we encourage the authors and their sponsors to clearly report the frequency of pooled and stratified adverse events and adverse reactions for all COVID-19 vaccine trials. Similarly, we also encourage journal reviewers and editors to carefully assess the reporting of these safety data. By providing this much needed information, patients and clinicians will be able to meet the challenge of indirectly comparing vaccine safety profiles. This safety information will enhance informed decisions about vaccine selection at the individual level, taking into consideration not only efficacy, but also the overall frequency and severity of adverse events. We note that some regulatory authorities, such as the US Food and Drug Administration and the European Medicines Agency, have made detailed COVID-19 vaccine safety data publicly available. These data, in addition to the rapidly emerging evidence from large-scale observational studies and spontaneous reports, will enhance our understanding of the comparative safety of the available COVID-19 vaccines. Observational studies are essential for assessing COVID-19 vaccine safety in populations with limited inclusion in randomized clinical trials such as very old and frail adults, pregnant women, and patients who are immunocompromised. To better inform the public, clinicians, and policy makers about the real-world comparative safety of COVID-19 vaccines, the Department of Health of Hong Kong has commissioned the COVID-19 Vaccines Adverse Events Response & Evaluation (CARE) Programme: a comprehensive real-time surveillance study that aims to closely monitor the known and potential adverse events following immunization with COVID-19 vaccines in Hong Kong [8] . NR not reported a Outcomes are for the two-dose regimen of Comirnaty 30 μg given 21 days apart. Adverse events within 7 days of the first dose were extracted from Figure 2 of Polack et al. [4] . The overall frequency of any adverse event was only reported for the overall safety population and not stratified by age group b Outcomes are for the two-dose regimen of CoronaVac 3 μg given 28 days apart (low dose). Adverse reactions were extracted from supplementary table 3-12 for the combined phase I/II trials (Zhang et al.) [2] and from supplementary table 3-3 for the phase II trial (Wu et al.) [1] reported within 28 days of the first dose c Outcomes are for the two-dose regimen of Vaxzevria (standard dose: 3.5-6.5 × 10 10 virus particles) given 28 days apart. Adverse reactions were solicited up to 7 days after the first dose. Specific adverse reactions were extracted from supplementary table S5-S7, while overall adverse events indicate any local or systemic adverse reaction for the priming dose (supplementary table S12) [3] . Results for the 56-69 and 70+ years of age groups were pooled 

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

E2A clinical safety data management: definitions and standards for expedited reporting. ICH harmonised tripartite guideline: international conference on harmonisation

The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI)

Covid-19 vaccines: safety surveillance manual. Geneva; 2020

COVID-19 Vaccines Adverse Events Response & Evaluation (CARE) Programme. 2021